Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.47%81.210.9%$648.72m
CELGCelgene Corporation
-10.76%121.331.1%$640.82m
AMGNAmgen Inc.
-0.63%182.961.1%$453.41m
BIIBBiogen Inc.
-1.26%338.101.2%$410.25m
REGNRegeneron Pharmaceuticals, Inc.
-1.81%432.982.7%$314.62m
VRTXVertex Pharmaceuticals Incorporated
0.02%154.631.9%$217.79m
INCYIncyte Corporation
-0.07%114.192.5%$202.03m
ALXNAlexion Pharmaceuticals, Inc.
-1.08%138.941.9%$183.38m
ALNYAlnylam Pharmaceuticals, Inc
-0.82%114.6810.7%$157.13m
EXELExelixis, Inc.
-1.06%27.176.5%$135.00m
ILMNIllumina, Inc.
2.29%209.883.5%$132.21m
BLUEBluebird Bio, Inc.
2.22%142.5517.3%$118.24m
BMRNBioMarin Pharmaceutical Inc.
-0.43%87.754.4%$113.37m
SRPTSarepta Therapeutics, Inc.
2.41%51.9416.9%$108.74m
CLVSClovis Oncology, Inc.
0.95%77.5016.5%$103.06m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.